The Nebraska Medical Association

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

The Nebraska Medical Association

https://www.nebmed.org/

Nebraska Oncology Society
The Nebraska Chapter of the American College of Cardiology
Nebraska Rheumatology Society
Medication-Assisted Treatment
Nebraska Dermatology Society
Nebraska Neurological Society
2024 Spring Meeting
Nebraska Radiological Society
Nebraska Association of Pathologists

Playback speed

10 seconds

2020 ASCO Updates on IO in Advanced Melanoma: What Are the Outcomes With Different Ipi+Nivo Combinations? How Do Targeted Therapy Agents Compare to IO? Does Pembro Lead to Lower irAEs?

By Nebraska Oncology Society FEATURING Shailender Bhatia

65 views

October 12, 2020

Comments 0

Hypothetical Patient Case: Hepatocellular Carcinoma with Progression…

Feat. J. Gutierrez, J. Strauss

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Feat. K. Hanna, J. Strauss

Nebraska Oncology Society

Targeted Therapy for mNSCLC: What Is the Response Rate With Selperca…

Nebraska Oncology Society

G. Riely

199 views

NSCLC Targeted Therapies Update: Should We Consider EGFR Targeted Th…

Nebraska Oncology Society

G. Riely

159 views

ASCO 2020 Review of Transoral Robotic Surgery for OPC : Is 2-yr PFS …

Nebraska Oncology Society

E. Sherman

13 views

2020 ASCO LA-HNSCC Trials Review: What Is the Efficacy of Weekly CDD…

Nebraska Oncology Society

E. Sherman

13 views

ASCO 2020 Update on DO-IMRT & HNC Metastatic: Does Change in IMRT Le…

Nebraska Oncology Society

E. Sherman

20 views

2020 ASCO Update on Metastatic/Recurrent HNSCC: What Is the Efficacy…

Nebraska Oncology Society

E. Sherman

15 views

2020 ASCO Update on RET-Altered Thyroid Cancer: What Is the Efficacy…

Nebraska Oncology Society

E. Sherman

25 views

Nebraska Oncology Society 2020 Update on Advanced UC: Is Atezo Benef…

Nebraska Oncology Society

N. Vogelzang

48 views

Nebraska Oncology Society 2020 Update on PC: Does 18F-DCFPyL-PET/CT …

Nebraska Oncology Society

N. Vogelzang

118 views

Nebraska Oncology Society 2020 Update on Advanced RCC: Is 1L Pembro+…

Nebraska Oncology Society

N. Vogelzang

170 views

2020 ASCO mCRC Updates Recap: Did We Experience Pseudoprogression Wi…

Nebraska Oncology Society

G. Kim

48 views

2020 ASCO Updates on GI Cancers: Is Chemo w/ mFOLFIRINOX More Effect…

Nebraska Oncology Society

G. Kim

13 views

2020 ASCO Highlights on Advanced CRC: Does mFOLFIRINOX Show DFS Bene…

Nebraska Oncology Society

G. Kim

15 views

2020 ASCO Updates on mCRC: Is Adjuvant mFOLFOX Superior to Hepatecto…

Nebraska Oncology Society

G. Kim

25 views

2020 ASCO Highlights on Stage 3 Colon Cancer: What Are the DFS/OS Di…

Nebraska Oncology Society

G. Kim

21 views

KEYNOTE-177 2020 ASCO Update on MSI-H/dMMR mCRC: Does Pembro Improve…

Nebraska Oncology Society

G. Kim

28 views

ES-SCLC 2020 Update: Which IO Options Showed Activity in Phase III T…

Nebraska Oncology Society

G. Riely

93 views

Stage IV NSCLC 2020 Update: Is There a Benefit to Short-Course Chemo…

Nebraska Oncology Society

G. Riely

122 views

2020 ASCO Updates on IO in Advanced Melanoma: What Are the Outcomes …

Nebraska Oncology Society

S. Bhatia

65 views

2020 ASCO Highlights on Neoadjuvant IO in Stage 3 Melanoma: Does Ipi…

Nebraska Oncology Society

S. Bhatia

43 views

2020 ASCO Updates on Frontline Multiple Myeloma: KRd vs. VRd - What …

Nebraska Oncology Society

A. Cohen

302 views

2020 ASCO Updates on R/R Myeloma: Does FDA-Approved Selinexor Offer …

Nebraska Oncology Society

A. Cohen

335 views